Search Results - "Konkle, B"

Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis by CHU, S. G., BECKER, R. C., BERGER, P. B., BHATT, D. L., EIKELBOOM, J. W., KONKLE, B., MOHLER, E. R., REILLY, M. P., BERGER, J. S.

“…See also Machin SJ, Briggs C. Mean platelet volume: a quick, easy determinant of thrombotic risk? This issue, pp 146–7. Summary.  Aim:  To determine whether an…”
Get full text

Progress toward meeting the needs of adolescent females with bleeding disorders by Konkle, B. A.

Get full text

Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review by Samuelson Bannow, B.T., Konkle, B.A.

“…Despite high rates of venous thromboembolism (VTE) among patients with hematologic malignancies, few tools exist to assist providers in identifying those…”
Get full text

Hepatitis C in haemophilia: time for treatment for all by Makris, M., Konkle, B. A.

Get full text

Recognizing the need for personalization of haemophilia patient-reported outcomes in the prophylaxis era by Recht, M., Konkle, B. A., Jackson, S., Neufeld, E. J., Rockwood, K., Pipe, S.

“…The safety and efficacy of treatment options for patients with haemophilia have significantly improved over the last two decades, particularly with greater…”
Get full text

Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories by Sommer, J. M., Moore, N., McGuffie-Valentine, B., Bardan, S., Buyue, Y., Kamphaus, G. D., Konkle, B. A., Pierce, G. F.

“…Summary Discrepancies exist for some of the modified coagulation factors when assayed with different one‐stage clotting and chromogenic substrate assay…”
Get full text

Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program by Stone, Mars, Di Germanio, Clara, Wright, David J, Sulaeman, Hasan, Dave, Honey, Fink, Rebecca V, Notari, Edward P, Green, Valerie, Strauss, Donna, Kessler, Debbie, Destree, Mark, Saa, Paula, Williamson, Phillip C, Simmons, Graham, Stramer, Susan L, Opsomer, Jean, Jones, Jefferson M, Kleinman, Steven, Busch, Michael P

“…Abstract Background The Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P) Epidemiology, Surveillance and Preparedness of the Novel…”
Get full text

Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project by Konkle, B. A., Johnsen, J. M., Wheeler, M., Watson, C., Skinner, M., Pierce, G. F.

“…Introduction Information from the genes encoding factor VIII (F8) and IX (F9) is used in reproductive planning and to inform inhibitor formation, bleeding…”
Get full text

Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis by James, A. H., Konkle, B. A., Kouides, P., Ragni, M. V., Thames, B., Gupta, S., Sood, S., Fletcher, S. K., Philipp, C. S.

“…Summary The aim of this study was to elucidate the fall in von Willebrand factor (VWF) and factor VIII activity (FVIII) after childbirth in women with and…”
Get full text

The HIT Expert Probability (HEP) Score: a novel pre‐test probability model for heparin‐induced thrombocytopenia based on broad expert opinion by CUKER, A., AREPALLY, G., CROWTHER, M. A., RICE, L., DATKO, F., HOOK, K., PROPERT, K. J., KUTER, D. J., ORTEL, T. L., KONKLE, B. A., CINES, D. B.

“…Background: The diagnosis of heparin‐induced thrombocytopenia (HIT) is challenging. Over‐diagnosis and over‐treatment are common. Objectives: To develop a…”
Get full text

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors by KONKLE, B. A., EBBESEN, L. S., ERHARDTSEN, E., BIANCO, R. P., LISSITCHKOV, T., RUSEN, L., SERBAN, M. A.

“…Background: Hemophilic patients with factor VIII (FVIII) and FIX inhibitors suffer from frequent bleeding episodes and reduced quality of life. Objectives: To…”
Get full text

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A by Nolan, B., Mahlangu, J., Perry, D., Young, G., Liesner, R., Konkle, B., Rangarajan, S., Brown, S., Hanabusa, H., Pasi, K. J., Pabinger, I., Jackson, S., Cristiano, L. M., Li, X., Pierce, G. F., Allen, G.

“…Introduction The safety, efficacy and prolonged half‐life of recombinant factor VIII Fc fusion protein (rFVIIIFc) in previously treated patients with severe…”
Get full text

Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program by Christopherson, Pamela A., Haberichter, Sandra L., Flood, Veronica H., Perry, Crystal L., Sadler, Brooke E., Bellissimo, Daniel B., Di Paola, Jorge, Montgomery, Robert R., Abshire, T, Weiler, H, Lillicrap, D, James, P, O’Donnell, J, Ng, C, Bennett, C, Sidonio, R, Manco‐Johnson, M, Journeycake, J, Zia, A, Lusher, J, Rajpurkar, M, Shapiro, A, Lentz, S, Gill, J, Leissinger, C, Ragni, M, Tarantino, M, Roberts, J, Hord, J, Strouse, J, Ma, A, Valentino, L, Boggio, L, Sharathkumar, A, Gruppo, R, Kerlin, B, Kulkarni, R, Green, D, Hoots, K, Brown, D, Mahoney, D, Mathias, L, Bedros, A, Diamond, C, Neff, A, DiMichele, D, Giardina, P, Cohen, A, Paidas, M, Werner, E, Matsunaga, A, Shafer, F, Konkle, B, Cuker, A, Kouides, P, Stein, D

“…Background Type 3 von Willebrand Disease (VWD) is a rare and severe form of VWD characterized by the absence of von Willebrand factor (VWF). Objectives As part…”
Get full text

Role of exercise and physical activity on haemophilic arthropathy, fall prevention and osteoporosis by FORSYTH, A. L., QUON, D. V., KONKLE, B. A.

“…In older men with haemophilia, arthropathy resulting from a lifetime of intra‐articular bleeding contributes to the loss of independence and increased…”
Get full text

Prophylaxis in real life scenarios by Fischer, K., Konkle, B., Broderick, C., Kessler, C. M.

“…Summary Prophylaxis has become the standard mantra of care for those individuals with severe haemophilia A and B. Primary prophylaxis is advocated to prevent…”
Get full text

Congenital factor VII deficiency: therapy with recombinant activated factor VII - a critical appraisal by MARIANI, G., KONKLE, B. A., INGERSLEV, J.

“…Congenital factor VII (FVII) deficiency is a rare bleeding disorder with high phenotypic variability, and optimal management has yet to be determined…”
Get full text

Factor VIII mutation and desmopressin-responsiveness in 62 patients with mild haemophilia A by Nance, D., Fletcher, S. N., Bolgiano, D. C., Thompson, A. R., Josephson, N. C., Konkle, B. A.

“…Summary Utilization of the synthetic vasopressin analogue (1‐deamino‐8‐D‐arginine‐vasopressin, DDAVP) in treatment of mild haemophilia A (MHA, specific…”
Get full text

Von Willebrand factor for menorrhagia: a survey and literature review by Ragni, M. V., Machin, N., Malec, L. M., James, A. H., Kessler, C. M., Konkle, B. A., Kouides, P. A., Neff, A. T., Philipp, C. S., Brambilla, D. J.

“…Background von Willebrand disease (VWD) is the most common congenital bleeding disorder. In women, menorrhagia is the most common bleeding symptom, and is…”
Get full text

A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand disease by Sood, S. L., James, A. H., Ragni, M. V., Shapiro, A. D., Witmer, C., Vega, R., Bolgiano, D., Konkle, B. A.

Get full text

The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A by SOUCIE, J. M., WANG, C., SIDDIQI, A., KULKARNI, R., RECHT, M., KONKLE, B. A.

“…Although body adiposity and disease severity in haemophilia have been found in cross‐sectional studies to be negatively associated with joint mobility, it is…”
Get full text